<DOC>
	<DOCNO>NCT01788176</DOCNO>
	<brief_summary>To evaluate efficacy safety use single , intravenous 5mg dose zoledronic acid manage pain Complex Regional Pain Syndrome patient .</brief_summary>
	<brief_title>The Use Zoledronic Acid Complex Regional Pain Syndrome</brief_title>
	<detailed_description>Complex regional pain syndrome ( CRPS ) disorder extremity characterize spontaneous unexplained disproportionate pain , hyperalgesia , swell , limited range motion , vasomotor instability , skin change , patchy bone demineralization.The incidence CRPS estimate 5.46 per 100,000 person year risk Olmsted County , Minnesota ( US ) , prevalence 20.57 per 100,000 , incidence general population Netherlands estimate much high , 26.2 per 100,000 person-years . The adverse effect serious lasted day . The beneficial effect bisphosphonates already document several placebo-controlled trial ; however , report use zoledronic acid reduce pain CRPS patient .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Somatoform Disorders</mesh_term>
	<mesh_term>Complex Regional Pain Syndromes</mesh_term>
	<mesh_term>Reflex Sympathetic Dystrophy</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>1 . Patients 18 year age gender , continue pain disproportionate inciting event , cardinal feature CRPS . 2 . Pain initial injury sign symptom present first visit 3 . History previous unsuccessful treatment pain , minimum two drug therapy , non steroidal antiinflammatory drug , steroid , antidepressant , central act analgesic , calcitonin sympathetic block , ( bisphosphonates ) least six month . 4 . Must report least one symptom three four follow category : 1 . Sensory : Reports hyperesthesia and/or allodynia 2 . Vasomotor : Reports temperature asymmetry and/or skin color change and/or skin color asymmetry 3 . Sudomotor/Edema : Reports edema and/or sweating change and/or sweat asymmetry 4 . Motor/Trophic : Reports decrease range motion and/or motor dysfunction ( weakness , tremor , dystonia ) and/or trophic change ( hair , nail , skin ) . 5 . Must display least one sign* time evaluation two follow category : 1 . Sensory : Evidence hyperalgesia ( pinprick ) and/or allodynia ( light touch and/or deep somatic pressure and/or joint movement ) 2 . Vasomotor : Evidence temperature asymmetry and/or skin color change and/or asymmetry 3 . Sudomotor/Edema : Evidence edema and/or sweat change and/or sweat asymmetry 4 . Motor/Trophic : Evidence decrease range motion and/or motor dysfunction ( weakness , tremor , dystonia ) and/or trophic change ( hair , nail , skin ) . 6 . Skin temperature affect side equal high nonaffected side . 7 . No diagnosis well explain sign symptom . 1 . Presence systemic disease include diabetes mellitus , hyperthyroidism , renal liver dysfunction , peripheral vascular cardiovascular disease , uncontrolled hypertension , rheumatoid hematopoietic disease , neurological disease related CRPS , overt alcohol addiction , positive pregnancy test and/or lactate woman , hyperparathyroidism , hypocalcaemia . 2 . Creatinine clearance &lt; 35mL/min , serum creatinine measure dose zoledronic acid . 3 . Preexisting hypocalcaemia disturbance mineral metabolism ( e.g . hyperparathyroidism , thyroid surgery , parathyroid surgery , malabsorption syndrome , excision small intestine ) . 4 . Hypersensitivity zoledronic acid component drug use trial . 5 . Patients asthma aspirinsensitivity 6 . Pregnancy unwillingness use contraceptive method trial 7 . Patients previously use kind bisphosphonate , especially zoledronic acid . 8 . Osteoporosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Complex Regional Pain Syndromes</keyword>
	<keyword>drug therapy</keyword>
	<keyword>zoledronic acid</keyword>
</DOC>